Effects of diazoxide in experimental acute necrotizing pancreatitis
Carregando...
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.72, n.2, p.125-129, 2017
Resumo
OBJECTIVE: We aimed to assess the effects of diazoxide on the mortality, pancreatic injury, and inflammatory response in an experimental model of acute pancreatitis. METHODS: Male Wistar rats (200-400 g) were divided randomly into two groups. Fifteen minutes before surgery, animals received physiological (0.9%) saline (3 mL/kg) (control group) or 45 mg/kg diazoxide (treatment group) via the intravenous route. Acute pancreatitis was induced by injection of 2.5% sodium taurocholate via the biliopancreatic duct. Mortality (n= 38) was observed for 72 h and analyzed by the Mantel-Cox Log-rank test. To study pancreatic lesions and systemic inflammation, rats (10 from each group) were killed 3 h after acute pancreatitis induction; ascites volume was measured and blood as well as pancreases were collected. Pancreatic injury was assessed according to Schmidt's scale. Cytokine expression in plasma was evaluated by the multiplex method. RESULTS: Mortality at 72 h was 33% in the control group and 60% in the treatment group (p = 0.07). Ascites volumes and plasma levels of cytokines between groups were similar. No difference was observed in edema or infiltration of inflammatory cells in pancreatic tissues from either group. However, necrosis of acinar cells was lower in the treatment group compared to the control group (3.5 vs. 3.75, p = 0.015). CONCLUSIONS: Treatment with diazoxide can reduce necrosis of acinar cells in an experimental model of acute pancreatitis, but does not affect the inflammatory response or mortality after 72 h.
Palavras-chave
Pancreatitis, Diazoxide, Rats
Referências
- Banks PA, 2016, PANCREAS, V45, P633, DOI 10.1097/MPA.0000000000000632
- Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
- Bhosale G, 2015, ANN NY ACAD SCI, V1350, P107, DOI 10.1111/nyas.12885
- Gukovsky I, 2012, J GASTROEN HEPATOL, V27, P27, DOI 10.1111/j.1440-1746.2011.07004.x
- Gurusamy KS, 2016, COCHRANE DB SYST REV, V4, DOI 10.1002/14651858.CD011383.pub2
- Iwai T, 2000, BRIT J PHARMACOL, V129, P1219, DOI 10.1038/sj.bjp.0703148
- Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8
- Llimona F, 2014, INFLAMMATION, V37, P1231, DOI 10.1007/s10753-014-9850-0
- Ma C, 2012, MOL MED REP, V6, P57, DOI 10.3892/mmr.2012.881
- Menozzi A, 2011, EUR J PHARMACOL, V650, P378, DOI 10.1016/j.ejphar.2010.09.078
- Minkov GA, 2015, PANCREAS, V44, P713, DOI 10.1097/MPA.0000000000000329
- Mukherjee R, 2016, GUT, V65, P1333, DOI 10.1136/gutjnl-2014-308553
- Murphy E, 2008, PHYSIOL REV, V88, P581, DOI 10.1152/physrev.00024.2007
- Murphy E, 2008, PHYSIOLOGY, V23, P115, DOI 10.1152/physiol.00044.2007
- Nagy K, 2004, J NEUROSCI RES, V76, P697, DOI 10.1002/jnr.20120
- Rahgozar M, 2001, J GASTROEN HEPATOL, V16, P290, DOI 10.1046/j.1440-1746.2001.02433.x
- Rios ECS, 2010, CLIN EXP PHARMACOL P, V37, P35, DOI 10.1111/j.1440-1681.2009.05220.x
- SCHMIDT J, 1992, INT J PANCREATOL, V12, P41
- SCHMIDT J, 1992, ANN SURG, V215, P44
- Moretti AIS, 2009, PANCREAS, V38, P507, DOI 10.1097/MPA.0b013e31819fef75
- van Acker GJD, 2006, WORLD J GASTROENTERO, V12, P1985
- Vanlangenakker N, 2008, CURR MOL MED, V8, P207, DOI 10.2174/156652408784221306
- Virgili N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075189
- Wang X, 2004, SHOCK, V22, P23, DOI 10.1097/01.shk.0000129200.30965.57
- Wu BU, 2011, CLIN GASTROENTEROL H, V9, P710, DOI 10.1016/j.cgh.2011.04.026